Adam Narloch speaks with Dr Michael Jordan to talk about his HLH research and a pivotal trial in HLH. Dr Jordan is a pediatric hematologist-oncologist at Cincinnati Children’s Hospital Medical Center and a professor in the Department of Pediatrics at the University of Cincinnati. Hear from Dr Jordan about his work exploring the pathology of HLH using mouse models, as well as the background, methods, and results from the Gamifant pivotal trial.

Indication

Gamifant is an interferon gamma (IFNγ)–blocking antibody indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy.

Important Safety Information

Infections

Before initiating Gamifant, patients should be evaluated for infection, including latent tuberculosis (TB). Prophylaxis for TB should be administered to patients who are at risk for TB or known to have a positive purified protein derivative (PPD) test result or positive IFNγ release assay.

Please see additional Important Safety Information and the full Prescribing Information for Gamifant at Gamifant.com.

©2023 Sobi, Inc. All rights reserved. NP-32204 12/23

Adam Narloch is joined by Dr. Saara Kaviany and Dr. Blachy J. Dávila Saldaña for a discussion about treating patients with HLH. Dr Kaviany is a pediatric hematologist-oncologist and an assistant professor of pediatrics at University of Chicago Medicine. Dr Saldaña is also a pediatric hematologist-oncologist and an associate professor of pediatrics at George Washington University. Hear from these 2 experts about the overall treatment goals and strategies for patients with HLH.

Follow Us

• YouTube @Sobi-Pharma
• Linkedin @Sobi

Presented by Sobi Inc.

www.sobi.com

©2023 Sobi, Inc. All rights reserved. NP-32204 12/23

Adam Narloch speaks with Dr Ashish Kumar and Dr Scott Canna to discuss the challenges involved with diagnosing and managing HLH. Dr Kumar is a pediatric hematologist- oncologist, and a director of the Histiocytosis Center at Cincinnati Children's Hospital. Dr Scott Canna is a pediatric rheumatologist and an Assistant Professor of Pediatrics at Children’s Hospital of Philadelphia. Hear from these 2 experts about why a prompt diagnosis is critical for patients with HLH—and why it can be so difficult to achieve.

Follow Us

• YouTube @Sobi-Pharma
• Linkedin @Sobi

Presented by Sobi Inc.

https://www.sobi.com/usa/en

©2023 Sobi, Inc. All rights reserved. NP-32204 12/23